• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Michael Hawthorne, PhD, Named Deputy Chief Executive Officer at Bakhu Holdings

    3/9/22 9:05:00 AM ET
    $PFE
    $SANG
    $SNY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Programming Data Processing
    Technology
    Get the next $PFE alert in real time by email

    LONG BEACH, CA / ACCESSWIRE / March 9, 2022 / Bakhu Holdings, Corp. (OTC:BKUH) today announced the appointment of Michael R. Hawthorne, PhD, 47, as Deputy Chief Executive Officer to primarily assist President and CEO Evripides Drakos in the Company's expansion plans.

    "Dr. Hawthorne is an international biopharma leader with strategic and operational skills ranging from launching start-up discovery biotech companies up to driving growth in global businesses employing more than 10,000 people," according to Drakos. "His experience in growing companies in the cell science space will be invaluable to our business," Drakos said.

    Bakhu Holdings has the exclusive North American rights to sublicense a process to grow select cannabinoids in proprietary bioreactors with consistent qualitative and quantitative attributes at what management believes is a significant discount to traditional cultivation and manufacturing processes.

    Upon onboarding, Dr. Hawthorne said: "I am pleased to join the management team to accelerate the transition from laboratory R&D and testing to full commercialization of the Bakhu patented process in order to maximize value for shareholders."

    Michael's initial duties will be to assist in capital markets coordination, applying developing technology to various licenses as well as assisting in day-to-day operations of the Company and financial reporting. Furthermore, he is charged with assisting in making introductions with regard to potential strategic business partners, sublicensees, joint venture partners and similar to create revenue streams for the Company. These tasks will also include plans to raise debt and/or equity capital when needed as well as exit strategies.

    Dr. Hawthorne was awarded Fellowship of The Royal Society of Biology (FRSB) in 2020 in recognition of his long-time contributions to global biosciences.

    In an almost thirty year career in the bioscience industry, Dr. Hawthorne has held senior global leadership positions in Pfizer (NYSE:PFE), Genzyme (NASDAQ:SNY) and Sangstat (NASDAQ:SANG). He has gone on to launch several VC-backed start-ups in the space, most recently Censo Biotechnologies, a cell science company which was acquired in March 2021. He is an adviser to several private equity companies including BG Capital (USA) and NovaBio (Switzerland). He is a retained adviser to a number of young healthcare companies, including Closed Loop Medicine Ltd (UK).

    Dr. Hawthorne earned his PhD from the University of Washington in Neuropharmacology in 2000. He received his undergraduate BSC degree with honors from the University of Newcastle-Upon-Tyne in Pharmacology in 1995.

    About Bakhu Holdings, Corp.

    Bakhu Holdings, Corp. (OTC:BKUH) holds a license to cell replication technology to produce, manufacture and sell cannabis-related products - sometimes referred in the industry as cannabinoids - exclusively in North and Central America and the Caribbean. The Company's business model to exploit this intellectual property is to sell royalty-based sub-licenses to properly-licensed third parties who will cultivate and manufacture cannabis products. They plan to incorporate the cell replication technology in production facilities that they fund, build and operate to produce medical, food additive and recreational cannabis-related products.

    Headquarters: One World Trade center, Suite 130, Long Beach, CA 90831. Phone: (310) 891-1959.

    Website: bakhuholdings.com
    Text: [email protected]
    Twitter: @BakhuHoldings
    Facebook: Bakhu Holdings Corporation
    LinkedIn: Bakhu Holdings Corporation

    Forward-Looking Statements

    This news release may contain forward-looking statements within the meaning of the Securities Act. As a general matter, forward-looking statements may reflect our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. These statements may be identified using forward-looking terminology such as "may", "will", "expects", "plans", "estimates", "anticipates", "projects", "intends", "believes", "outlook" and similar expressions. The forward-looking statements contained in this news release are based upon our historical performance, current plans, estimates, expectations and other factors we believe are appropriate under the circumstances. The inclusion of this forward-looking information is inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy and some of which might not even be anticipated. Future events and actual results, financial and otherwise, may differ materially from the results discussed in the forward-looking statements. Statements regarding the following subjects, among others, may be forward-looking: our business and investment strategy; our projected operating results; estimates relating to our ability to make distributions to our stockholders in the future and economic trends.

    INVESTOR RELATIONS CONTACT:

    GREG McANDREWS & ASSOCIATES
    Gregory A. McAndrews
    (310) 804-7037
    [email protected]

    SOURCE: Bahku Holdings, Corp.



    View source version on accesswire.com:
    https://www.accesswire.com/692082/Michael-Hawthorne-PhD-Named-Deputy-Chief-Executive-Officer-at-Bakhu-Holdings

    Get the next $PFE alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PFE
    $SANG
    $SNY

    CompanyDatePrice TargetRatingAnalyst
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    Sanofi
    $SNY
    4/15/2025$65.00Outperform
    Exane BNP Paribas
    Sanofi
    $SNY
    3/21/2025$65.00Neutral
    Goldman
    Sanofi
    $SNY
    1/30/2025Sell → Hold
    Deutsche Bank
    Pfizer Inc.
    $PFE
    12/10/2024$29.00Neutral
    BofA Securities
    Pfizer Inc.
    $PFE
    11/15/2024$25.00Underperform
    Wolfe Research
    Pfizer Inc.
    $PFE
    10/25/2024$30.00Neutral
    Citigroup
    Pfizer Inc.
    $PFE
    10/17/2024$32.00Mkt Perform
    Bernstein
    More analyst ratings

    $PFE
    $SANG
    $SNY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Chairman & CEO Bourla Albert

      4 - PFIZER INC (0000078003) (Issuer)

      7/16/25 6:20:20 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Taraporevala Cyrus

      4 - PFIZER INC (0000078003) (Issuer)

      7/2/25 4:39:02 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Smith James C

      4 - PFIZER INC (0000078003) (Issuer)

      7/2/25 4:38:59 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PFE
    $SANG
    $SNY
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • March 28, 2025 - FDA Approves Novel Treatment for Hemophilia A or B, with or without Factor Inhibitors

      For Immediate Release: March 28, 2025 Today, the U.S. Food and Drug Administration approved Qfitlia (fitusiran) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without factor VIII or IX inhibitors (neutralizing antibodies).“Today’s approval of Qfitlia is significant for patients wi

      3/28/25 10:17:55 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • February 14, 2025 - FDA Approves First Rapid-Acting Insulin Biosimilar Product for Treatment of Diabetes

      For Immediate Release: February 14, 2025 Today, the U.S. Food and Drug Administration approved Merilog (insulin-aspart-szjj) as biosimilar to Novolog (insulin aspart) for the improvement of glycemic control in adults and pediatric patients with diabetes mellitus. Merilog, a rapid-acting human insulin analog, is the first rapid-acting insulin biosimilar product approved by the FDA. As a rapid-acting insulin, Meri

      2/14/25 3:00:13 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for SOLIQUA 100/33 issued to SANOFI-AVENTIS US

      Submission status for SANOFI-AVENTIS US's drug SOLIQUA 100/33 (SUPPL-14) with active ingredient INSULIN GLARGINE; LIXISENATIDE has changed to 'Approval' on 11/01/2024. Application Category: BLA, Application Number: 208673, Application Classification:

      11/4/24 4:49:34 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PFE
    $SANG
    $SNY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      2/14/25 5:16:36 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Gottlieb Scott bought $28,240 worth of shares (1,000 units at $28.24), increasing direct ownership by 11% to 10,000 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      10/31/24 4:06:54 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Gottlieb Scott bought $79,401 worth of shares (3,000 units at $26.47), increasing direct ownership by 50% to 9,000 units (SEC Form 4)

      4 - PFIZER INC (0000078003) (Issuer)

      12/19/23 9:31:01 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PFE
    $SANG
    $SNY
    SEC Filings

    See more
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      7/22/25 8:49:32 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      7/18/25 6:03:36 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Sanofi

      6-K - Sanofi (0001121404) (Filer)

      7/2/25 8:25:36 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PFE
    $SANG
    $SNY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Cantor Fitzgerald initiated coverage on Pfizer with a new price target

      Cantor Fitzgerald initiated coverage of Pfizer with a rating of Neutral and set a new price target of $24.00

      4/22/25 8:03:45 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exane BNP Paribas initiated coverage on Sanofi with a new price target

      Exane BNP Paribas initiated coverage of Sanofi with a rating of Outperform and set a new price target of $65.00

      4/15/25 12:40:46 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Goldman initiated coverage on Sanofi with a new price target

      Goldman initiated coverage of Sanofi with a rating of Neutral and set a new price target of $65.00

      3/21/25 8:12:02 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PFE
    $SANG
    $SNY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-Adapted COVID-19 Vaccine in the European Union

      Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulationsUpon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and olderTo date, over a billion adults and children around the world have received the Pfizer-BioNTech COVID-19 vaccine, which continues to demonstrate a favorable safety and efficacy profile supported by extensive real-world evidence, clinical, non-clinical, pharmacovigilance and manufacturing dataDoses will be ready to sh

      7/25/25 2:30:00 AM ET
      $BNTX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Pfizer and BioNTech Receive Positive CHMP Opinion for LP.8.1-adapted COVID-19 Vaccine in the European Union

      Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulations Upon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and older To date, over a billion adults and children around the world have received the Pfizer-BioNTech COVID-19 vaccine, which continues to demonstrate a favorable safety and efficacy profile supported by extensive real-world evidence, clinical, non-clinical, pharmacovigilance and manufacturing data Doses will

      7/25/25 2:30:00 AM ET
      $BNTX
      $PFE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Pfizer's 'Depo-Provera' Increases Risk of Brain Tumours 3.5 Times Compared to Combined Birth Control Pill According to New Study as Litigation Overseen by Levin Papantonio Rises to Over 550 Lawsuits

      A study published on 29 June 2025 in international peer reviewed medical journal Expert Opinion on Drug Safety by Frey et al. has found that use of Pfizer's Depo-Provera (DMPA) for more than one year is associated with a 3.5-fold increased risk of developing an intracranial meningioma, a type of brain tumour, compared with the use of certain combined birth control pills1.Global pharmaceutical company Pfizer Inc. (NYSE:PFE), manufacturer of Depo-Provera, is facing a multidistrict litigation (MDL No.3140) in the USA, currently comprising over 550 lawsuits against the company by women who used Depo-Provera for more than one year and developed a meningioma.The number of lawsuits has increased fr

      7/24/25 7:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PFE
    $SANG
    $SNY
    Financials

    Live finance-specific insights

    See more
    • Pfizer Declares Third-Quarter 2025 Dividend

      Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 third-quarter 2025 dividend on the company's common stock, payable September 2, 2025, to holders of the Common Stock of record at the close of business on July 25, 2025. The third-quarter 2025 cash dividend will be the 347th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery,

      6/25/25 5:30:00 PM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Invites Public to View and Listen to Webcast of August 5 Conference Call with Analysts

      Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, August 5, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Second Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the confere

      6/25/25 10:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

      Pfizer Inc. (NYSE:PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. Eastern Daylight Time. To listen to the webcast, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. The transcript and webcast replay of the discussion will be made available on our web site at www.pfizer.com/investors within 24 hours after the end of the live discussion and will be accessible for at least 90 days.

      6/2/25 10:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PFE
    $SANG
    $SNY
    Leadership Updates

    Live Leadership Updates

    See more
    • Sanofi Appoints James Guy as Country Lead, Canada and General Manager, Specialty Care

      TORONTO, June 9, 2025 /CNW/ - Sanofi Canada today announced the appointment of James Guy as Country Lead, Canada and General Manager, Specialty Care. In this role, Guy will lead Sanofi's Canada Country Council, which manages the operations of the company's three business units and functions. Guy will also head the Specialty Care business unit in Canada. James Guy Country Lead, Canada and General Manager, Specialty Care "This is an exciting time in Sanofi's history, with the potential for our promising pipeline to deliver several scientific breakthroughs that can improve healt

      6/9/25 10:00:00 AM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Dexcom Appoints Jon Coleman as Chief Commercial Officer

      DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

      3/25/25 4:05:00 PM ET
      $DXCM
      $MASI
      $PFE
      Medical/Dental Instruments
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Biotechnology: Pharmaceutical Preparations
    • FoRx Therapeutics Appoints Chief Medical Officer and Provides an Update on Its Lead Development Candidate

      Industry veteran in clinical development of oncology therapeutics, Dr. Jens Wurthner, PhD, joins as Chief Medical Officer Lead development candidate, FORX-428, a PARG inhibitor for solid tumors, maintains progress toward IND submission by mid-2025 FoRx Therapeutics AG, a Swiss-based company committed to discovering and developing innovative drugs targeting cancer-relevant DDR (DNA Damage Response) pathways, today announced that it has appointed Jens Würthner, MD PhD, as Chief Medical Officer. He is further strengthening FoRx Therapeutics' existing management team with CEO Tarig Bashir, CSO Frank Zenke, and Head of Chemistry Ulrich Lücking. Jens Würthner has 20+ years of clinical devel

      2/26/25 9:00:00 AM ET
      $PFE
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PFE
    $SANG
    $SNY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sanofi

      SC 13G/A - Sanofi (0001121404) (Subject)

      11/7/24 2:49:36 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sangoma Technologies Corporation

      SC 13G/A - Sangoma Technologies Corp (0001753368) (Subject)

      10/7/24 2:30:02 PM ET
      $SANG
      Computer Software: Programming Data Processing
      Technology
    • SEC Form SC 13G filed by Sanofi

      SC 13G - Sanofi (0001121404) (Filed by)

      5/31/24 4:30:55 PM ET
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care